心脏代谢多病症与死亡率的关联
, Emanuele Di Angelantonio1, Stephen Kaptoge1
1University of Cambridge, Cambridge, England.
JAMA
|July 8, 2015
概括
心脏代谢多病症显著减少预期寿命. 患有糖尿病,中风或心肌梗塞 (MI) 等两种疾病会使预期寿命减少12年,而这三种疾病都会使预期寿命减少15年.
科学领域:
- 心血管疾病流行病学
- 公共卫生研究 公共卫生研究
- 长寿研究的研究.
背景情况:
- 随着心脏代谢多病发病率的增加,这给公众健康带来了重大挑战.
- 了解多种心脏代谢疾病对预期寿命的影响对于预防策略至关重要.
研究的目的:
- 量化与心脏代谢多病症相关的预期寿命缩短.
- 分析与糖尿病,中风和心肌梗塞 (MI) 结合的死亡风险.
主要方法:
- 利用来自新兴风险因素协作 (近70万参与者) 和英国生物银行 (50万参与者) 的个人参与者数据.
- 对于有或没有心脏代谢疾病的个体,根据年龄和性别调整的死亡率和危险比率 (HRs) 的计算.
- 通过将HRs应用于美国特定年龄的死亡率来估计累积存活率.
主要成果:
- 60岁时任何两种心脏代谢疾病 (糖尿病,中风,心脏病发作) 的病史与预期寿命减少12年有关.
- 患有这三种疾病 (糖尿病,中风,心脏病发作) 的人在60岁时,预期寿命减少了15年.
- 随着每种额外的疾病,死亡风险都增加了,与参考组相比,所有原因死亡率的HRs从1.9到6.9不等.
结论:
- 心脏代谢多病症显著降低了预期寿命.
- 糖尿病,中风和心脏病发作对死亡风险的综合影响是多重的,导致寿命显著减少.
- 公共卫生干预应专注于预防和管理这些疾病,以减轻它们对预期寿命的影响.
相关概念视频
01:30Coronary Artery Disease I: Introduction
1.7K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.7K
01:29Cardiomyopathy V: Interprofessional Care
670
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
670
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
748
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
748
01:25Cardiomyopathy I: Introduction and Classification
834
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
834
01:30Cardiomyopathy II: Dilated Cardiomyopathy
783
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
783
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
852
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
852